Gilbert A. Fuller
About Gilbert A. Fuller
Gilbert A. Fuller (age 84) is an independent director of Security National Financial Corporation (SNFCA), serving on the Board since 2012. He is a former Executive Vice President, Chief Financial Officer, and Secretary of USANA Health Sciences, Inc. (2006–2008), and has served on USANA’s Board since 2008. He holds a B.S. in Accounting and an M.B.A. from the University of Utah. The Board has designated him an “audit committee financial expert” under Item 407(d) of Regulation S-K, reflecting deep accounting and finance credentials .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| USANA Health Sciences, Inc. | Executive Vice President, Chief Financial Officer, and Secretary | 2006–2008 | Senior finance leadership at a NYSE-listed multinational; drove finance, accounting, and corporate strategy |
| USANA Health Sciences, Inc. | Senior Vice President | 1999–2006 | Promoted from VP Finance; expanded corporate finance responsibilities |
| USANA Health Sciences, Inc. | Vice President of Finance | 1996–1999 | Led finance function during growth; pre-CFO track |
External Roles
| Organization | Role | Public/Private | Start Year | Notes |
|---|---|---|---|---|
| USANA Health Sciences, Inc. | Director | Public (NYSE) | 2008 | No SNFCA related-party transactions disclosed with USANA; reduces conflict risk |
Board Governance
- Independence: The Board affirmatively determined Fuller is independent under Nasdaq listing standards .
- Committee assignments (2024 activity levels in parentheses):
- Audit Committee — Chair; designated Audit Committee financial expert; met 3x in 2024 .
- Compensation Committee — Member; all independent directors; met 3x in 2024 .
- Nominating & Corporate Governance Committee — Member; all independent directors; met 2x in 2024 .
- Executive Committee — Member; met 1x in 2024 .
- Attendance: Board met 5 times in 2024; all directors attended all meetings except one absence by another director, implying 100% attendance by Fuller .
- Leadership structure: CEO also serves as Chair; no standing lead independent director, though independent directors meet in executive session and H. Craig Moody is designated to preside at those sessions .
Fixed Compensation
Director cash compensation and equity by year (outside director):
| Metric | 2023 | 2024 |
|---|---|---|
| Fees Earned or Paid in Cash ($) | $38,250 | $45,450 |
| Stock Awards ($) | $3,567 | $8,165 |
| Option Awards ($) | $0 | $0 |
| Total ($) | $41,817 | $53,615 |
- Program terms: Outside Directors receive $43,200 annual retainer plus $750 per day for certain management and Audit Committee meetings; annual equity choice of 1,000 options or 241 RSUs, and in 2024 an additional grant of 9,400 options or 2,268 RSUs at the director’s election; retirement benefit equals one month of director’s fees per year of service .
Performance Compensation
- Director equity program is time-based (not performance-based). Options vest 25% per quarter over one year; RSU vesting for directors may be under one year following a 2023 plan amendment (shorter vesting can weaken long-term alignment) .
- Fuller’s outstanding director equity:
| Equity Metric | As of 2023 | As of 2024/2025 |
|---|---|---|
| Options to purchase Class A common stock (outstanding) | 39,090 options | 41,045 options |
| Restricted Stock Units (outstanding) | 2,245 RSUs | 2,969 RSUs |
| Option vesting schedule | 25% quarterly over 1 year | 25% quarterly over 1 year |
| RSU vesting policy for directors | Allowed vesting < 1 year (amendment in 2023) | Allowed vesting < 1 year (amendment in 2023) |
Other Directorships & Interlocks
| Company | Sector | Role | Potential Interlock/Conflict |
|---|---|---|---|
| USANA Health Sciences, Inc. | Nutritional supplements | Director | No related-party transactions between SNFCA and USANA disclosed; low direct conflict with SNFCA’s insurance, mortgage, and memorial services businesses |
Expertise & Qualifications
- Former public-company CFO and corporate secretary; decades of finance, accounting, and corporate strategy experience .
- Audit Committee Chair and “financial expert,” indicating depth in internal controls, audit oversight, and financial reporting .
- Advanced education in accounting and business (B.S. Accounting; M.B.A.) .
Equity Ownership
| Metric | 2024 | 2025 |
|---|---|---|
| Class A Shares Beneficially Owned | 53,691 (<1%) | 40,601 (<1%) |
| Options Outstanding (Class A equivalent) | 39,090 | 41,045 |
| RSUs Outstanding | 2,245 | 2,969 |
- No pledge footnotes are disclosed for Fuller in the beneficial ownership tables (pledging would be a red flag if present) .
Insider Trading and Section 16(a) Notes
| Year | Event/Observation | Detail |
|---|---|---|
| 2023 | Late Section 16 filings | One late filing upon vesting and sale of RSU shares; one upon exercise of an option (administrative timeliness issue; amounts/dates not provided) |
| 2024 | Section 16(a) compliance summary | Company’s review did not list Fuller among late filers for 2024 (others were cited) |
Governance Assessment
-
Strengths
- Independent director with strong financial acumen; Audit Committee Chair and SEC-defined financial expert; signed Audit Committee Report; supports robust financial reporting oversight .
- Full board attendance in 2024; high engagement metrics across committees with multiple meetings held (Audit 3x; Comp 3x; Nominating 2x; Executive 1x) .
- Committees (Compensation and Nominating) are fully independent; aligns with governance best practices .
- Say-on-pay support was very strong in 2023 (approx. 98.6% approval), reflecting investor comfort with compensation oversight (Fuller serves on the Compensation Committee) .
-
Watch items / potential red flags
- Combined CEO/Chair structure persists; no standing lead independent director (though an independent director presides over executive sessions). This structure centralizes authority and may reduce independent counterbalance on sensitive matters .
- Family relationships among executives and directors (Quist family and a relative) represent a structural independence risk; oversight by independent directors like Fuller is critical in mitigating perceived conflicts .
- Director RSUs permitted to vest in under one year after 2023 amendment; shorter vesting can diminish long-term alignment compared to multi-year vesting (particularly for directors) .
- Proposed expansion of the 2022 Equity Incentive Plan by 3,000,000 shares implies up to 12.71% dilution on a fully converted basis; Compensation Committee and Board (including Fuller) supported the proposal—investors may scrutinize equity overhang and burn rate trends .
-
Related-party exposure
- No related-person transactions disclosed involving Fuller; Audit Committee (which he chairs) reviews and approves related-party transactions; 2024 disclosures focus on transactions involving Quist family members serving as executives .
-
Compensation committee process
- Compensation Committee composed solely of independent directors (including Fuller); for the 2024 equity plan amendment, neither the Board nor the Compensation Committee retained an outside consultant—investors may prefer independent advisor input on potentially dilutive equity authorizations .
Overall: Fuller enhances board effectiveness as an independent financial expert and Audit Chair with strong attendance and broad finance experience. Key governance risks relate to combined CEO/Chair structure, family interlocks among management/directors, shorter director RSU vesting, and equity plan dilution; continued strong committee oversight and transparent communication are important mitigants .